Podcasts about peter maccallum cancer centre

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.  Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode.  Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence.  Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor.  Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group.   For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group.  The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases.  The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them.  The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma.  Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks.  Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination.  These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report.  The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia.   Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis.  Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%.  The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed.  This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context.  Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker:   Dr. John Sweetenham   Follow ASCO on social media:    @ASCO on Twitter   @ASCO on Bluesky   ASCO on Facebook   ASCO on LinkedIn    Disclosures:   Dr. John Sweetenham:   No relationships to disclose  

In the first episode of a special daily series during the 2025 ASCO Annual Meeting, Dr. John Sweetenham discusses the results of 2 studies on the treatment of advanced colorectal cancer plus an additional study exploring the association of Medicaid expansion with cancer survival outcomes. Transcript Dr. John Sweetenham: Hello, and welcome to our special coverage of the 2025 ASCO Annual Meeting on the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham, and I'll be bringing you brief analysis on selected abstracts from each day of the Meeting. My disclosures are available in the transcript of this episode.  Today, I'll be reviewing three abstracts, the first two of which address the treatment of advanced colorectal cancer. Today's first study is Abstract 3501. These data were presented by Dr. Heinz-Josef Lenz from the USC Norris Comprehensive Cancer Center and report on the expanded analysis of the CheckMate-8HW trial. This was a phase 3, international, multicenter trial in patients with MSI-high/MMR-deficient metastatic colorectal cancer, who were randomized between nivolumab (nivo) alone, nivolumab plus ipilumomab (ipi) or investigators' choice of chemotherapy (FOLFOX or FOLFIRI) with or without bevacizumab or cetuximab. The study showed that nivo plus ipi demonstrated superior progression-free survival compared with chemotherapy in the first-line setting and superior progression-free survival compared with nivo alone across all lines of therapy. These results led to the approval of nivo + ipi in the first-line setting in patients with MSI-H/dMMR mCRC in the U.S., the EU, and many other countries.  In today's presentation, Dr. Lenz reported on the expanded analyses of nivo plus ipi versus nivo across all lines of therapy and longer follow-up results for nivo and ipi versus chemo in the first-line setting. With longer follow up (the median is now at 47 months) nivo and ipi continued to show progression-free survival benefit compared with chemotherapy with a median PFS of 54.1 months versus 5.9 months, for a hazard ratio of 0.21.  Additionally, the analysis of the effects on PFS2, defined as the time from randomization to progression after subsequent systemic therapy, start of second subsequent systemic therapy, or death, showed that compared with chemotherapy, first-line nivo and ipi was associated with a 72% reduction in the risk of death or disease progression, despite the fact that 71% of those who progressed following chemotherapy crossed over to receive subsequent immunotherapy. The study also showed that across all lines, nivo and ipi demonstrated superior progression-free survival compared with nivo alone, the median not reached versus 39.3 months, for a hazard ratio of 0.62. No new toxicity signals emerged after further analysis. Most treatment-related adverse events with possible immune etiology were observed within the first six months of therapy. The results for PFS2 are particularly significant. Up to now, there has been some reluctance to use nivo and ipi as first-line therapy, partly because of its toxicity profile and based on the rationale that it would be active after other frontline therapies. The observation in this study that the beneficial effects of nivo and ipi are maintained downstream is compelling. The results suggest that delaying the use of this combination to the second line or later may compromise subsequent PFS and supports the use of nivo and ipi as a standard-of-care frontline option for MSI-H/dMMR metastatic colorectal cancer. Moving on, the next study I'm featuring today is Abstract 3503, presented by Dr. Jeanne Tie from the Peter MacCallum Cancer Centre and the Walter and Eliza Hall Medical Institute of Medical Research from Melbourne, Australia. This study reported the impact of circulating tumor DNA (ctDNA)-guided adjuvant chemotherapy escalation in stage III colon cancer, focused on the primary analysis of the ctDNA-positive cohort from the randomized DYNAMIC-III trial. As background, about 30% of patients with stage III colon cancer will recur following standard-of-care adjuvant therapy with oxaliplatin-based regimens. And current data show that for those patients with high-risk disease, 6 months of chemotherapy is associated with a lower recurrence rate than 3 months. Circulating tumor DNA following initial surgery has been shown to be a strong independent prognostic factor for these patients, but questions remain about how ctDNA can be used for adaptation of treatment. Questions regarding treatment adaptation were addressed in the DYNAMIC-III trials – specifically, does treatment escalation benefit those who are ctDNA positive following surgery, and can therapy be de-escalated for those who are ctDNA negative. The first of these 2 questions – treatment escalation in the positive group – is the subject of this report. One thousand and two patients were randomized in this study, between ctDNA-informed therapy (502) or standard management (500). Of those patients included in the intent to treat cohorts, 129 were ctDNA positive in the ctDNA-informed arm compared with 130 in the standard management arm. Various pre-planned treatment escalation protocols were used, depending on the choice of first-line therapy. With a median follow up of 42.2 months, there was no difference in 3-year relapse free survival between the ctDNA informed group (48%) and the standard management group (52%). There was, however, a highly significant difference in relapse-free survival for patients who cleared ctDNA by the end of treatment compared with those who didn't. The authors concluded that the recurrence risk for this group remains high, at about 50%, after adjuvant therapy and that it increases with higher ctDNA burden, but treatment escalation didn't appear to reduce the recurrence risk. Clearance of ctDNA was associated with a favorable outcome, suggesting that as more effective treatments are developed in the future for this group, ctDNA will likely prove to have major utility. Changing gears now, my final selection for today is Abstract 11006, presented by Dr. Elizabeth Shafer from the American Cancer Society. This study explored the association of Medicaid expansion with 5-year survival after a cancer diagnosis.  Dr. Schafer began her presentation by providing some historical perspective on the impact of the Affordable Care Act on reducing the number of uninsured adults aged less than 65 years in the United States. She then reviewed some recent data on the impact of Medicaid expansion on cancer care, including improved screening rates, improved access to cancer surgery, and an increase in earlier cancer diagnosis. The current study builds on earlier data from the American Cancer Society which showed improved 2-year overall survival for patients with newly diagnosed cancer following Medicaid expansion. The new study reported by Dr. Schafer examined 5-year cause-specific survival in individuals with cancer since Medicaid expansion, analyzed according to cancer type and various demographic and social factors. Using data from more than 813,000 individuals from 26 states that expanded Medicaid compared with more than 610,000 from 12 states that did not, the authors reported that similar improvements in 5-year cause-specific survival were observed in the expansion and the non-expansion states, but when analyzed by other factors, differences in outcome emerged. For example, although similar improvements in survival between expansion and non-expansion states were seen in urban communities, there was a significant improvement of 2.55 percentage points in survival for individuals in rural communities in expansion states compared with those in non-expansion states. Similar trends were observed in high poverty areas, where improvements in survival were superior in expansion versus non-expansion states.  When examined by cancer type, the authors observed greater improvements in 5-year survival for those with pancreatic, lung, and colorectal cancer, possibly due to improvements in screening and early access to treatment.  The authors concluded that those residing in rural and high-poverty areas experienced the most improvement in cause-specific cancer survival following Medicaid expansion. In summary, it's encouraging to see an improving trend in cancer mortality overall, independent of Medicaid expansion, but it's also important to remember that this is yet another study which confirms how implementation of the ACA has improved cancer outcomes and begun to address some of the disparities in cancer care. Join me again tomorrow to hear more top takeaways from ASCO25. And if you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:  Dr. John Sweetenham    Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn        Disclosures:  Dr. John Sweetenham:  No relationships to disclose 

In this episode of 'Conversations in Lung Cancer Research,' Professor Tom John from the Peter MacCallum Cancer Centre in Melbourne discusses the significant progress and excitement surrounding cancer vaccines, particularly their emerging role in lung cancer treatment.He is joined by Professor Ken O'Byrne, a medical oncologist and clinical scientist at the Princess Alexandra Hospital and Queensland University of Technology, and Professor Georgina Long AO, the medical director of the Melanoma Institute of Australia and co-recipient of the 2024 Australian of the Year.The experts delve into technological advances spurred by COVID-19 vaccine development, promising results from recent melanoma and lung cancer vaccine trials, and the potential for personalised neoantigen mRNA vaccines. They also discuss historical challenges in vaccine efficacy and the promising future of immunotherapy and cancer vaccines, including patient perspectives and the logistics of rapid vaccine production and distribution.00:00 Introduction03:15 Historical Context of Cancer Vaccines05:13 Technological Advances in Vaccine Development06:53 The Promise of mRNA Technology14:03 Personalised vs. Off-the-Shelf Vaccines18:02 Identifying Neoantigens for Vaccines21:13 Caution and Optimism in Vaccine Development23:18 Exploring Tumour Mutation Burden and Vaccine Bias29:35 Challenges and Opportunities in Metastatic Disease33:53 Immunotherapy and Vaccine Hesitancy37:52 Future of Cancer Vaccines and Rapid Innovation42:14 Conclusion and Final Thoughts

Look who popped into the GU Cast studio this week for a chat about where we are going next with radioligand therapy (RLT) for prostate cancer! Professors Oliver Sartor (Mayo Clinic, Rochester) and Michael Hofman (Peter Mac, Melbourne), are two of the world's most pre-eminent experts in the world of RLT for prostate cancer. They were each respectively PIs  on the VISION and TheraP RCTs published in NEJM and Lancet in 2021, and both have many ongoing trials in RLT for prostate cancer. We hear in which stages of prostate cancer LuPSMA is next likely to be approved, and some discussion about exciting trials soon to read out. We also discuss other RLTs including actinium and terbium, combinations, imaging technology for patient selection, AI, and the word "cure" even gets a mention. A very entertaining and exciting discussion with two of the best in the business. Your regular hosts are Professor Declan Murphy and Dr Renu Eapen, Urologists at Peter MacCallum Cancer Centre, Melbourne.This is a Themed Podcast supported by our Silver Partners, Novartis. Even better on our YouTube channelLinks:Michael's paper in the Journal of Nuclear Medicine:"The Hierarchy of SUVs: From Diagnostics to Therapeutics and the Pathway to Effective Theranostics"

This piece comes from Melbourne, Australia, at the World Congress of Prehabilitation and Perioperative Medicine, held alongside the Australian ERAS+ Conference. Hear about the significance of multidisciplinary collaboration in prehabilitation and research; grants for virtual surgery schools; the impact of diet and microbiome on cancer pathways, and the future of digital prehabilitation. The conversation emphasizes the importance of optimizing patient care and reducing complications through innovative approaches in prehabilitation and perioperative medicine. Presented by Kate Leslie and Mike Grocott with their guests Bernard Riedel, an academic anaesthesiologist and the Director of the Department of Anaesthesia, Perioperative Medicine, and Pain Medicine at Peter MacCallum Cancer Centre in Melbourne, Australia, he holds a Professorial appointment at the University of Melbourne and Linda Denehy, Professor of Physiotherapy at the University of Melbourne, she has a joint appointment as Professor of Health Services Research: Allied Health at the Peter MacCallum Cancer Centre Melbourne.

Bev has over 20 years’ experience across the Australian and global biopharmaceutical & healthcare sectors. She holds a PhD in molecular medicine with additional qualifications in genetic counselling, project management and decision analysis. Bev commenced her career with Postdoctoral roles in cancer research at Memorial Sloan Kettering Cancer Centre and the Peter MacCallum Cancer Centre, before moving to genetic counselling practice and then commercial roles in research & development, portfolio management and strategic partnerships in the pharmaceutical industry. Throughout this conversation Menner outlines how being an adopted child shaped her upbringing to want to explore genetics on a deeper level and how she became fascinated through science. Menner's company Cell Therapies is on the cusp of new breakthroughs everyday as she outlines. See omnystudio.com/listener for privacy information.

Genomics explores the building blocks of human DNA, in the hopes of uncovering patterns that can lead to lifesaving medical discoveries. 

Send us a textWelcome to Episode 28 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.Are you talking to your patients about sex enough? Research suggests that most healthcare professionals aren't having these conversations as often as patients would like. Sexual health should be a core component of holistic patient care.To shed light on this critical topic, Rachael is joined by Associate Professor Safeera Hussainy, Senior Pharmacy Research Manager at the Peter MacCallum Cancer Centre in Melbourne, Australia.From lifestyle changes and psychosocial interventions to hormone replacement therapies, lubricants, and sexual aids, learn about the diverse approaches to enhancing sexual satisfaction and body image. Emphasizing the critical role healthcare professionals must play in addressing these topics to provide comprehensive care and break through the barriers of taboo and stigma. With great resources and top tips on how to approach communications with patients and their partners about how treatment will impact sexuality. We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.

Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation. CME information and select publications here (https://www.researchtopractice.com/EGFRNSCLCThinkTank2024)

In this TOGA podcast, we provide an overview of the treatment options for rare subtypes of oncogene driven NSCLC that are now readily identified in the MBS-reimbursed small gene panel including NTRK1, 2,3 and other rare mutations in NSCLC. The importance of testing all patients is discussed as well as what to do when resistance occurs. Associate Professor Steven Kao, Medical Oncologist from Chris O'Brien Lifehouse and Clinical Associate Professor Sydney Medical School, Faculty of Medicine and Health is joined by Professor Wendy Cooper, senior staff specialist in Tissue Pathology and Diagnostic Oncology at Royal Prince Alfred Hospital in Sydney, Anatomical Clinical Stream Lead for NSW Health Pathology, a Clinical Professor at the University of Sydney and a Conjoint Professor at the University of Western Sydney and also Professor Ben Solomon head of the lung Medical Oncology Service and a Group Leader of the Molecular Therapeutics and Biomarkers Laboratory in the Research Division at Peter MacCallum Cancer Centre as well as a Founding Board member of TOGA.

Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.

Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/InsideTheIssue2024/ALKPosNSCLC).

Our Editor in Chief Sue Yom hosts a discussion of two related articles, "Diagnostic CT-Enabled Planning (DART): Results of a Randomized Trial in Palliative Radiation Therapy" and its accompanying editorial, "'Sim-free' Palliative Radiation Therapy Greatly Reduces Time Burden for Patients." Guests are Melissa O'Neil, MSc, MRT(T), an Advanced Practice Radiation Therapist and Leader of the Rapid Response Clinic at London Health Sciences Center in Canada, who was the first author of the DART trial publication, as well as Dr. Katrina Woodford, Lead Radiation Therapist Clinician Scientist at the Peter MacCallum Cancer Centre, Honorary Senior Fellow at the University of Melbourne and Adjunct Senior Lecturer at Monash University, and first author of the accompanying editorial.

Richard Zinn is a Cosmetic and Reconstructive Plastic Surgeon with a special expertise in breast reconstruction as well as augmentation. Richard is well trained both locally and internationally, and is highly experienced with 2 postgraduate fellowships in breast surgery, microsurgery and general plastic surgery. He maintains involvement in both public and private centres, and is actively involved in training junior surgeons at the Northern Hospital, Royal Melbourne Hospital and Peter MacCallum Cancer Centre.  In this episode, we chat about: - What plastic surgery is, and the procedures involved  - Biggest misconceptions about plastic surgery  - Cosmetic vs reconstructive plastic surgery explained  - The effects of Ozempic on liposuction demand  - Most common and in-demand procedures for different age groups  - Cosmetic tourism  - Fat grafting for breast implants / breast reconstruction & augmentation  - Plastic surgery post pandemic  - Richard Zinn Plastic Surgery practice & business  - Why Richard became a plastic surgeon + study & career path  - How to find a balance between a busy career and your life  – Follow The Founder Tapes on Instagram, TikTok and LinkedIn Subscribe to The Founder Tapes on YouTube!  – Find Richard Zinn Plastic Surgery:  Website: https://richardzinnplasticsurgery.com.au/  Instagram: @richardzinnplasticsurgery LinkedIn: /in/richard-zinn-85994280/  – Music License Number - QK7rZS

To celebrate the Paris 2024 Olympics, we bring you this special Olympics-themed episode of GU Cast - our very own Prostate Cancer Olympics! Yes we We are joined in the GU Cast studio by Dr Elena Castro, GU Medical Oncologist at Hospital 12 de Octubre in Madrid, who happened to be passing through Melbourne. And by our own A/Professor Arun Azad, GU Medical Oncologist at Peter MacCallum Cancer Centre, and one of our GU Cast Clinical Advisors. We have three events and some great medal contenders, but who will win Gold??!! Tune in for some great discussion and debate, and some surprises and controversies along the way. This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson Pharmaceuticals. Even better on our Youtube channel 

This conversation gets our coverage of the Evidence Based Perioperative Medicine, World Congress, (EBPOM) 2024 off to a great start. Shared decision making is a topic which cuts right to the centre of perioperative medicine with a focus upon patients and patient perspectives. Presented by Andy Cumpstey with his guests, Bob Evans, a retired Chartered Town Planner and local authority director, a board member of the Centre for Perioperative Care (CPOC), founder member of the Patient, Carer and Public Involvement and Engagement (PCPIE) group, Debra Leung, staff specialist anesthetist at the Peter MacCallum Cancer Centre, Melbourne, Australia and Alf Collins, Freelance health consultant, communication skills trainer and former National Clinical Director of Personalized Care and Shared Decision Making for NHS England.

Los hallazgos de un ensayo clínico internacional dirigido por Peter MacCallum Cancer Centre en Australia, han demostrado que un nuevo fármaco podría ser clave en la lucha contra el cáncer de pulmón. Escucha esta y otras noticias positivas de la semana.

Join this week's Radiotherapy team Training Wheels, Cyber Siouxz and Miss Peri Neum, as they speak to Dr David Speakman, a specialist breast and melanoma surgeon and the Chief Medical Officer at the Peter MacCallum Cancer Centre, as he discusses the effects of AI programming in cancer research and the improvements that the Peter Mac Cancer Centre has undergone over time. They also speak to Dr Harriet Beevor about her work with voluntary assisted dying (VAD) at Peter Mac, and what the process entials since the VAD Victorian Legistaltion came into effect in June 2019.

In the first episode of a special daily series during the 2024 ASCO Annual Meeting, Dr. John Sweetenham shares highlights from Day 1, including exciting data on the CROWN trial in NSCLC, the ASC4First study in chronic myeloid leukemia, and the effects of high-deductible health plans on cancer survivorship. TRANSCRIPT Dr. John Sweetenham: I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast. I'm delighted to bring you a special series of daily episodes from the 2024 ASCO Annual Meeting and to share my top takeaways on selected abstracts.   Today, I'll be reviewing exciting new data in chronic myeloid leukemia, remarkable outcomes for patients with ALK-positive non-small cell lung cancer, and a compelling study on the effects of high deductible health plans on cancer survivorship.   My disclosures are available in the transcript of this episode.   LBA6500, the ASC4FIRST trial, is a phase 3 combination of asciminib with the current standard of care tyrosine kinase inhibitors, those being imatinib, nilotinib, dasatinib and bosutinib for the first line treatment of patients with chronic myeloid leukemia. The data from this large multinational study, conducted in 29 countries, were presented by Dr. Timothy Hughes from the Royal Adelaide Hospital in Australia. Some patients with chronic phase CML respond well to tyrosine kinase inhibitor therapy, and about one-third may eventually be able to stop therapy and will remain in remission, the so-called treatment free remission or TFR. Unfortunately, almost half of patients eventually need to change therapy due to resistance and intolerance, and most patients will need to remain on therapy for many years, possibly for life.  Asciminib is the first BCR-ABL1 inhibitor to specifically target the ABL myristate pocket or STAMP and was designed to be highly potent but also highly specific, thus minimizing side effects and toxicity. In this large trial, which is the first randomized head-to-head comparison of asciminib with other tyrosine kinase inhibitors, 405 patients were randomized 1:1 to receive either asciminib at a dose of 80 milligrams daily or another investigator-selected TKI. The groups were well balanced for all patient characteristics, including ELTS risk. The primary objectives of the study were to compare the major molecular response rate at 48 weeks with an additional analysis for the patients who received imatinib as the investigator-selected TKI. With median follow-up at 16.3 months for patients receiving asciminib and 15.7 months for those receiving the other TKIs, the 48-week MMR rates were 68% for asciminib compared with 49% for the other investigators-selected TKIs.  The rates of MR4 after 48 weeks, a deep molecular response which is a prerequisite to be considered for treatment free remission, were 39% for asciminib compared to 21% for the investigator-selected TKI. Tolerability and safety were excellent for asciminib, with only 5% discontinued due to toxicity compared to 10% for the other TKI arm. Frequently observed toxicities with asciminib included thrombocytopenia and neutropenia. The investigators concluded that asciminib is the only agent to show a statistically significant improvement in efficacy and toxicity in this patient group when compared with all other TKIs, and that asciminib has the potential to become the preferred standard of care for the first line treatment of CML. Follow-up on the study continues, but there is no question that these are exciting and probably practice-changing results.  The next exciting study, LBA8503, was presented by Dr. Benjamin Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia. This presentation was an update of the CROWN study for patients with previously untreated advanced ALK-positive non-small cell lung cancer. Lorlatinib is a third-generation brain-penetrating ALK inhibitor which was compared with crizotinib in the CROWN-3 study. This phase 3 study enrolled 296 patients randomly assigned to lorlatinib 100 milligrams once daily or crizotinib 250 milligrams twice daily. The interim results showed a 72% reduction in the risk for progression or death with lorlatinib compared with crizotinib and formed the basis for the March 2021 FDA approval of the drug for metastatic ALK positive non-small cell lung cancer. A subsequent post hoc analysis at three years showed continued progression free survival benefit with lorlatinib compared with crizotinib.  Earlier today, Dr. Solomon presented a further post hoc analysis of the study at 60.2 months of median follow-up. Among the entire patient population, the median PFS was not reached with lorlatinib compared with 9.1 months with crizotinib. At 60 months, the PFS rate was 60% with lorlatinib compared with only 8% with crizotinib. The PSF benefits with lorlatinib were seen across all patient subgroups. The improved control of central nervous system metastatic disease, which was observed in the earlier reports, has been confirmed in this recent analysis. Among those patients with baseline brain metastases, the median PFS with lorlatinib was not yet reached compared with six months with crizotinib. More than half of patients with baseline brain metastases were progression free at 60 months.   But the benefit of lorlatinib is certainly not confined to patients with brain metastases. Lorlatinib also significantly improved progression-free survival among patients without metastases. At 60 months, 63% of patients without baseline brain metastases assigned to lorlatinib were progression free, compared with only 10% of those assigned crizotinib. These are remarkable results. As Dr. Solomon stated in his conclusion, 60% of patients on lorlatinib are still progression free and 92% are progression free in the brain. No new safety signals were seen and the improved efficacy over crizotinib was seen across all risk groups. These results are unprecedented in patients with ALK-positive non-small cell lung cancer.   Concerning data were presented today by Dr. Justin Barnes from Washington University. Dr. Barnes presented results from a retrospective study in Abstract 11005 which showed whether a patient with cancer has high-deductible health insurance can play a role in their survival. Although previous studies have shown care disparities for those with high-deductible plans, this report focuses specifically on effects on survival and concludes that cancer survivors with high-deductible health plans had a greater risk of mortality both overall and from cancer. High-deductible insurance was defined as costing between $1,200 and $1,350 annually for individual insurance, or between $2,400 and $2,700 annually for a family plan. Investigators used data from the U.S. National Center for Health Statistics National Health Interview Survey and linked them to files from the National Death Index to determine mortality rates. Included were more than 147,000 respondents aged between 18 and 84 years who did not have Medicaid. Among these individuals, 5.9% were cancer survivors. The concern for cancer survivors with these plans is that in addition to recurrence that could require costly treatments, there might be issues related to survivorship. Investigators found that overall survival was worse for those with a cancer diagnosis coupled with high-deductible health insurance, with a hazard ratio of nearly 1.5.   But when the researchers reviewed data from the general population without a history of cancer, they didn't find any association between high-deductible health insurance and outcomes. According to Dr. Barnes, the leading hypothesis is that patients with cancer who have a high-deductible plan delay workup for a potential new or recurrent cancer diagnosis or postpone or avoid other care. The results also indicated that survival among certain subgroups, such as non-Hispanic white patients, patients with higher incomes, and patients with at least a college or high school education, was worse for those with a high-deductible health plan, not the groups who are typically impacted by care disparities. It is possible that these individuals are more likely to select high-deductible health plans and that having these plans might counteract what might otherwise be adequate access to care.  A key take-home from this analysis is that cancer patients and survivors, whatever their racial, ethnic, or socioeconomic status, should have access to health plans with low deductibles and should be informed of the potential risks of their long-term health and survival when covered by high-deductible plans.   Join me again tomorrow to hear more top takeaways from ASCO24. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review and subscribe wherever you get your podcasts.   Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness

In the first of our special episodes focussing on GU Oncology in China, we are delighted to welcome our inaugural GU Cast China Editor. Professor Yao Zhu, to the GU Cast studio. Yao is a Urologist at Fudan University Shanghai Cancer Centre,  and is well known to all of us at GU Cast and Peter MacCallum Cancer Centre. As part of our Gold Partnership with Bayer Pharmaceuticals in China, Yao will help us put together some Themed Podcasts focussing on GU Oncology in China. This first episode focuses on one of our favourite topics, metastatic hormone-sensitive prostate cancer (mHSPC). We chat with Yao and special guest, Professor Ning Zhang (Beijing Anzhen Hospital, affiliated to Capital Medical University), and learn a lot about prostate cancer in China! Even better on our YouTube channel 

Radiation therapy can be a very effective treatment for lung cancers, with 77% of patients indicating for radiation therapy in their disease trajectory. Yet, only 40% of patients with lung cancer in NSW receive radiation therapy.In this podcast, Professor Shalini Vinod, Assoc Professor Mei-Ling Yap, and Dr Clare Bajraszewski  discuss why radiation therapy is underutilised in lung cancer, what this means for patients, and potential solutions to address this.This episode's host are:Professor Shalini Vinod is a Radiation Oncologist at Liverpool Hospital and a Conjoint Professor at the South Western Sydney Clinical School, UNSW Sydney. She is also on the Board of Directors at TOGA.Associate Professor Mei-Ling Yap is a senior staff specialist Radiation Oncologist at Liverpool and Macarthur Cancer Therapy Centres in Sydney.Dr Clare Bajraszewski is a Radiation Oncologist at Peter MacCallum Cancer Centre at the Bendigo campus.Want to read more about radiation therapy?  Radiation OncologyRadiation Therapy TreatmentsRadiotherapy underutilisation and its impact on local control and survival in New South Wales, AustraliaA Population-based Model of Local Control and Survival Benefit of Radiotherapy for Lung Cancer     

Hello and welcome to Episode 211 of the People Powered Business Podcast! In today's episode I am joined by Mel Rosenthal, professional coach for founders, leaders and teams.Mel is a Professional Certified Coach, accredited by the International Coaching Federation and an Australian Institute of Company Directors graduate (GAICD). She holds a Bachelor of Commerce (First Class Honours) from the University of Western Australia and an MBA from the Kellogg School of Management at Northwestern University. Mel works with Founders and Leaders to drive growth for companies and the people in them. She has been trusted by the leadership of companies including Who Gives A Crap, Minor Figures, Keep Cup, StartUp Victoria, QBE, Tyro, Champion Life, Thoughtworks, The Australian Centre for Social Innovation, Inventium, Advisian, Peter MacCallum Cancer Centre, Walter and Eliza Hall Institute of Medical Research, Swinburne University, Alinta Energy, ME Bank, Visy and Medtronic.Mel is also the creator of 52 Conversations – a card game to create conversations that matter – and that's what our conversation focused on today. Mel shares some stunning statistics that reflect the real costs and risks of not having important conversations with our teams, and shares her insights into how leaders can have more effective and impactful conversations.To leave more about the 52 Conversations Card Game, simply head to this site:https://www.52conversations.com/To learn more about Mel, the work she does and how you can connect with her, head to this website:https://melissajrosenthal.com/Or you can connect on LinkedIn here:https://www.linkedin.com/in/rosenthalmelissa/An InvitationWould you like to connect with other like-minded business owners, leaders and managers experiencing similar situations with their team? Join the discussion inside our free Facebook Group – HR Support for Australian -Businesses. https://www.facebook.com/groups/hrsupportaustralia

In this podcast, UROONCO RCC chief editor Dr. Carmen Mir (ES) interviews Prof. Michael Hofman from the Peter MacCallum Cancer Centre, Australia, on the results of his study “First-in-human safety, imaging and dosimetry of [68Ga]Ga-DPI-4452, a novel CA IX-targeting peptide, in patients with clear cell renal cell carcinoma (ccRCC)”. Prof. Hofman discusses the data he presented at ASCO GU24 in San Francisco and suggests that these first-in-human findings with radiolabelled DPI-4452 are encouraging for the subsequent evaluation of treatment with [177Lu]Lu-DPI-4452.[68Ga]Ga-DPI-4452 provides exceptional images in patients with ccRCC without clinically significant toxicity. Very high SUVs and tumour-to-background ratios suggest potential for use in both diagnostics and patient selection for therapy. The tumour retention and rapid elimination support potential of [177Lu]Lu-DPI-4452 radioligand therapy. For more details on this study, you can read the abstract on the UROONCO Kidney Cancer educational platform.

Welcome to Episode 27 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Endometrial cancer is the most common gynaecological cancer in Australia and advanced disease and early on set disease is increasing.In today's episode, our Host Rachael Babin is joined by Professor Linda Mileshkin Director of Medical oncology at the Peter MacCallum Cancer Centre in Melbourne, Australia.They discuss new treatment options, clinical trials and collaborative research efforts such as the EDEN initiative. They also discuss stigma, shame and society's silence around gynaecological cancers.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

Senior Editor Owen Stretton talks to Professor Shankar Shiva from the Peter MacCallum Cancer Centre in Melbourne about the International Society of Stereotactic Radiosurgery's new systematic review and practice guidelines for stereotactic body radiotherapy in primary renal cell carcinoma.Continue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Prof Fred Saad (University of Montreal) drops in to chat about the interesting condition that is non-metastatic castration-resistant prostate cancer (nmCRPC). Which men are at risk of developing metastases? When should we use an AR pathway inhibitor? Why PSMA PET/CT should NOT be used. And hear his thoughts on "dabbling" in prostate cancer! Also joined by Professor Shankar Siva and Dr Louise Kostos from Peter MacCallum Cancer Centre. Hosted as ever by Dr Renu Eapen and Professor Declan Murphy. Fred was on a speaker tour in Australia supported by Bayer Pharmaceuticals and this Themed Podcast is supported by Bayer, Silver Partners of GU Cast.Even better on our YouTube channel

The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion.Even better on our YouTube channel Thanks to all the LuTectomy team and to all of our fantastic patients. And huge thanks to our funders.Funding/Support: This investigator-initiated study was funded by the Movember Foundation, the Australian Government Medical Research Future Fund (MRFF) with contribution from the EJ Whitten Foundation and Novartis.Acknowledgements: We thank the medical, surgical, nursing, nuclear medicine, and administrative staff of all the departments at the Peter MacCallum Cancer Centre who were involved in this trial. We thank the patients who agreed to participate in the study. PSMA-617 was supplied by Novartis and no carrier added 177Lu by the Australian Nuclear Science and Technology Organisation (ANSTO). We remember and thank the late Dr John Violet for his involvement including study conception and design.Links:LuTectomy paper in European Urology LuTectomy Editorial 

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.Read the full article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00390-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanoncContinue this conversation on social!Follow us today at...https://twitter.com/thelancet & https://Twitter.com/TheLancetOncolhttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

I'm honoured to welcome Renee Barnes to the podcast this week. Renee is the founder of The People Paradox, an organisation that supports small to medium sized businesses to set up their people foundations for growth. She has 20 years of strategic and operational People and Culture experience in both public and private organisations, spanning businesses like Marsh Insurance, Parks Victoria, Aesop, Peter MacCallum Cancer Centre and Art Series Hotels and she is a Board Member of Aspergers Victoria. She is passionate about creating engaging workplaces where people are enabled to succeed. Her clients range from Fin Tech, the Music Industry, the Courts, Research and Development Corporations, all the way through to contemporary retail businesses demonstrating her adaptable approach to shaping workforce strategies and people programs that suit her client's needs.  Renee also has a vision to reduce gender disadvantages experienced by mothers whilst on parental leave. She is developing the FOUND Program which is a digital education program that supports and empowers mothers to navigate their matrescence before returning to the workplace to achieve better outcomes for mothers, families, employers and communities.     In this episode, Renee shares her business story. We talk about workplace culture, communication, leadership and how Renee is supporting, educating and coaching mothers to return to work.  WE DISCUSS Meaningful living and Renee talks about what success means to her. Why Renee started The People Paradox. What workplace culture is, how it's influenced and how it's formed in businesses of all sizes. The specific channels that can be used to reform and change workplace culture. How communication is a primary lever of change.  What makes a great business leader? Renee explains matrescence, how it impacts women and the extraordinary work she is doing to support, educate and coach mothers through this period of significant change. How the current ways of working are not working and the importance of creating workplaces that are accessible, flexible and that help people turn up and be the best version of themselves. The importance of helping women step into their personal power and educating mothers on how to use language to make sure they exemplify the skills and capabilities they acquire during time away from the office.  LEAVE A REVIEW ON APPLE PODCASTS If you enjoy the podcast, I invite you to leave a review on Apple Podcasts or wherever you listen to your podcasts. Let me know how the podcast inspires, empowers and supports you to communicate meaningfully, create success and experience more ease, joy and meaning in your life and business. Leave a review with your favourite episode, biggest learning, most inspiring moment or ‘aha' moment. I invite you to follow or subscribe to the show to be notified when new episodes are released.    SHOW NOTES   Get all episode show notes here:   www.debrashepherd.com.au/debra-shepherd-podcast   CONNECT WITH RENEE www.peopleparadoxhr.com Instagram @found_learningmotherhood CONNECT WITH DEBRA  www.debrashepherd.com.au Instagram @_DebraShepherd      

ที่รัฐวิกตอเรียมีศูนย์ดูแลผู้ป่วยโรคมะเร็งโดยเฉพาะชื่อ Peter MacCallum Cancer Centre คุณศนิธิ (ใบเตย) ตันธรรศกุล พยาบาลฝ่ายค้นคว้าวิจัยเล่าถึงการทำงานพื่อหายารักษามะเร็ง และเราใกล้ที่จะสามารถหายารักษาโรคนี้ได้หรือยัง

This is for hardcore PSMA aficionados!! This is the 7th of our ProsTIC/Prostate Cancer Foundation Global Webinars focussing on all things PSMA theranostics (you can find the rest in our back catalogue stretching back to April 2020). We peek into theranostics beyond what we currently have with beta-emitters like LuPSMA, into the tantalising world of alpha-PSMA theranostics. Multidisciplinary researchers from the PCF-funded TACTICAL project give a sneak into current and future work. Hear from Memorial Sloan Kettering Cancer Center experts Prof Mike Morris, Dr Lisa Bodei and Dr Jason Lewis about very exciting developments in DLL3 imaging and theranostics in neuroendocrine prostate cancer;  Dr Marwa Rahimi (Radiochemist at Peter MacCallum Cancer Centre) and David Pattison (Nuclear Medicine Physician, Royal Brisbane Hospital), overview Lead-212 targeted alpha therapy; and Dr Megan Crumbaker (Medical Oncologist (St Vincent's Hoapital, Sydney) who discusses Actinium-225 clinical data. Plus Dr James Buteau (Nuclear Medicine Physician, Peter Mac) on the Q&A Co-hosted by Declan Murphy and Michael Hofman from the GU Cast studio in Melbourne. along with Dr Howard Soule and Dr Andrea Miyahira from the PCF in California. Even better as a video podcast 

Editor-in-Chief Dr. Sue Yom hosts a discussion this month on the role of radiotherapy in the optimal treatment of recurrent and refractory lymphoma. Guests include Dr. Belinda Campbell, the journal's Section Editor of lymphoma and hematologic malignancies, Honorary Clinical Associate Professor at The University of Melbourne, and Deputy Director of Radiotherapy at Peter MacCallum Cancer Centre. We are joined by Dr. Mario Levis, Assistant Professor in the Department of Oncology from the University of Turin and first author of a paper in this month's issue, Peri-transplant radiotherapy in refractory or relapsed Hodgkin lymphoma patients undergoing autologous stem cell transplant: long term results of a retrospective study of the Fondazione Italiana Linfomi. Our other guest is Dr. Jennifer Peterson, Associate Professor in the Department of Radiation Oncology at Mayo Clinic Florida, who is the supervising author of another paper this month, Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma.

With approvals and reimbursement increasing all the time for the use of AR pathway inhibitors (ARPIs) in metastatic hormone-sensitive prostate cancer (mHSPC), we chat today about how front-line clinicians need to make sure we are making the most of these opportunities for our patients. Urologists in particular are the clinicians who most frequently diagnose men with metastatic prostate cancer, and who therefore need to be aware of the changing opportunities to improve outcomes for our patients. Today in this Themed Episode supported by our Gold Partner, Janssen, we chat with Professor Fred Saad, Chair and Professor of Urology at the University of Montreal, who says it is "unethical to treat newly diagnosed metastatic prostate cancer with ADT alone"! We are also joined by Dr Ciara Conduit, Medical Oncologist at Peter MacCallum Cancer Centre, who helps us understand management options for these patients. Also available as a video podcast on our YouTube channel 

Editor-in-Chief Dr. Sue Yom hosts Dr. Shankar Siva, Associate Professor and Radiation Oncologist from the Peter MacCallum Cancer Centre, Australia and the supervising author of "Cost-Effectiveness of Single- versus Multi-Fraction SABR for Pulmonary Oligometastases - The SAFRON II Trial"; Dr. David Sher, Professor at the University of Texas Southwestern Medical Center and the Red Journal's Methodology Section Editor who first-authored this month's OncoScan "The Cost-Effectiveness of Consolidative Radiation Therapy in Oligometastatic Disease: High-Value Proposition or Wishful Thinking?"; and Dr. Aisling Barry, Professor and Chair of Radiation Oncology at University College Cork and Cork University Hospital, Ireland, who first-authored "The Impact of Disease Progression on Health-Related Quality of Life Outcomes in Patients with Oligo-Metastatic Disease at 12-Months post Stereotactic Body Radiotherapy."

Dr Martin Nguyen completed his anaesthetic training at Western Health in Victoria and underwent his fellowship at the Peter MacCallum Cancer Centre in Victoria, Australia. He specializes in anaesthesia for orthopaedic, thoracic, general and upper gastrointestinal, plastic, urology, ear, nose and throat, and paediatric surgery. Martin is clinician innovator who has a deep passion for solving complex problems in healthcare using technology. He holds leadership positions in clinical research, medical education and hospital governance. Martin is also the founder of Medical Pantry, which is what we will be exploring in this episode - a hundred percent volunteer run Australian charity, that redistributes surplus medical supplies to disadvantaged communities globally, reduces healthcare's environmental impact and improves access to quality healthcare globally. Medical Pantry has recently donated a significant shipment of medical supplies to Ukraine to help innocent people impacted by war. He shared his experiences, challenges and plans for the future with Hanya Oversby last week. For more information on Martin, please click on this link https://www.linkedin.com/in/martin-h-nguyen/?originalSubdomain=au To find out more about Medical Pantry and donate to this fantastic cause https://medicalpantry.org/ To make a tax deductible donation to help the people of Ukraine https://www.ukrainecrisisappeal.org/ More information about Hanya Oversby can be found on https://hanyaoversby.com.au/ This episode of The Doctor Diaries Podcast was proudly sponsored by Medical Mecca, a new health practitioner owned and run online platform that involves individual health practitioners creating an online profile, similar to a Facebook/linked in profile, to make it easier for prospective patients to search and book into a suitable health care provider. Medical Mecca also allows for any health practitioner listed on the platform to send referrals to each other quickly, safely and efficiently. For more information please see www.medicalmecca.com.au

"Prostate Specific" Membrane Antigen PET/CT - now also available to stage kidney cancer! We seriously need a name change here. Already we know that PSMA PET/CT shows a lot more than the prostate/prostate cancer, but could it have utility in staging renal cancer?? We've certainly had a lot of off-trial experience of this at Peter MacCallum Cancer Centre since 2014, and we know see data  in Eur Urol Open Science to describe this experience. We are joined by senior author Associate Professor Shankar Siva, radiation oncologist at Peter MacCallum Cancer Centre, Dr Rana McKay, GU medical oncologist at the University of California, San Diego, who has an interest in FOLH1 expression in renal cancer, and Peter Mac nuclear medicine physician Professor Michael Hofman, to discuss PSMA and renal cancer. Check out this episode on YoutubeLinks:Prof Siva's paper in Eur Urol Open Science

A great episode focussing on two aspects of bladder cancer. Bladder preservation for muscle-invasive cancer is in the limelight again following the recent update of the landmark BC2001 trial. We chat with bladder cancer gurus Dr Neha Vapiwala, Radiation Oncologist at the University of Pennsylvania, Dr Ashish Kamat, Urologist at MD Anderson Cancer Centre, and Dr Nathan Lawrentschuk, Urologist at Peter MacCallum Cancer Centre and the Royal Melbourne Hospital. Everything you need to know! Plus a chat about the fascinating Bladder Path study presented by Dr Nick James at ESMO22, challenging the role of TURBT in managing bladder cancer. Spicy! And of course, Dr Aoife McVey pops up with her Twitti-Leaks section (yes she has given it a name)! Even more enjoyable on YouTube 

Dr Shom Goel is a clinician-scientist at the University of Melbourne and Peter MacCallum Cancer Centre, with a strong interest in Translational Breast Cancer Research. He was a guest speaker at the 2022 Breast Cancer Trials Annual Scientific Meeting and we asked Dr Goel to explain his research in CDK4/6 inhibitors and where research is going in the future.

It wasn't that long ago that we would have scoffed at the idea of using radiation therapy to treat primary kidney cancer. Not any more!! We are joined by two top experts in kidney cancer, and leaders of ongoing research in this field, to discuss the expanding role for radiation therapy in managing primary renal cancer. Dr Rana McKay, GU Medical Oncologist at the University of California, San Diego, and Associate Professor Shankar Siva, Radiation Oncologist at Peter MacCallum Cancer Centre in Melbourne, take us through the relatively recent history of radiation for renal cancer and highlight some ongoing trials in this area. A fantastic overview for anyone interested in renal cancer. Plus our intrepid social media watcher, Dr Aoife McVey, pops in to tell us what has caught her eye on Twitter this week. You can watch us broadcasting from our studio here on Youtube. Links:Twitter - Dr Rana McKay Twitter - A/Prof Shankar Siva Twitter - Dr Aoife McVeyTwitter - CheatUrologyTwitter - GoumasUrologiahttps://urologycheatsheets.org/ 

International speaker tours are back! And this week we had two fantastic GU oncology experts visiting Australia to do a lecture tour on hot topics in metastatic prostate cancer.  So of course we invited them to attend our multidisciplinary team meeting at Peter MacCallum Cancer Centre, then pop upstairs to teh Gu Cast studio.Dr Tian Zhang from UT Southwestern in Dallas, and Dr Rahul Aggarwal from UCSF, are both prolific medical oncologists with a huge amount of expertise in prostate cancer. We asked them to highlight three key areas in each of metastatic hormone-sensitive prostate cancer, and metastatic castration-resistant prostate cancer, to avoid us having to wade through teh endless stream of data in these fast-moving areas. What areas did they chose to highlight?? Well have a listen!Also posted on YouTube

While there is no way to prevent breast cancer, there are steps that can be taken to lower one's risk of being diagnosed, particularly for women with a strong family history or those who carry a gene mutation. Dr Wanda Cui is a Medical Oncologist at the Peter MacCallum Cancer Centre and is researching into breast cancer prevention within the risk management clinic. We asked Dr Cui to explain her research on Breast Cancer Prevention.

JB and Billy are live from the San Remo Hotel!, All Sports Report including footy, golf and cricket, Damian Barrett has the details on a big day at Essendon, and wraps up AFL Round 22, San Remo Hotel Owner Pete Williams, former AFL star Cam Pedersen, the finals JB wants to see, All-Australian discussion, Carlton's Sam Docherty, Rosie's social media feedback, the San Remo Hotel Quiz, Billy's JokeSee omnystudio.com/listener for privacy information.

GU Cast is pleased to cross-post another of these excellent ProsTIC PSMA theranostics webinars in collaboration with the Priotate Cancer Foundation's Global Knowledge Exchange programs. This webinar focuses on the new era of PSMA theranostics post-FDA approval. This webinar is co-hosted by Professor Michael Hofman, Nuclear Medicine Physician and Director of ProsTIC at Peter MacCallum Cancer Centre in Melbourne, and GU Cast's own Professor Declan Murphy, with comments from the PCFs Dr Howard Soule and Dr Andrea Miyahira.  Special guest presenters include Professor Silke Gillessen, Professor Ken Herrmann, and Dr Louise Kostos and Dr James Buteau. For all the slides and visual bits, enjoy on Youtube here 

In his third and final podcast from Lugano, Declan chats with Dr Axel Merseberger (Lubeck), Dr Jochen Walk (Marseille), Ms Jane Fisher (Melbourne), and Dr Chris Sweeney (Boston/Adelaide). Plus listen out for fantastic father and son act, Professor Joe and Oisin O'Sullivan, who played for the crowds outside the Villa Cian. Silke Gillessen and Aurelius Omlin were also pleased to announce the dates of the next APCCC which will take place from 25-27 April 2022 in spectacular Lugano. GU Cast is our regular podcast brought to you by Professor Declan Murphy and Dr Renu Eapen, Urologists at Peter MacCallum Cancer Centre in Melbourne. Available on all major podcasting platforms. Now also cross-posting on YouTube. https://gucast.buzzsprout.com/ Also cross-posted on YoutubeLinks:APCCC Website SAGENCI 

Welcome to another episode of The Words Matter Podcast.If you're enjoying the Clinical Reasoning Series and the podcast more generally, please consider supporting the show via Patreon. You can pledge as little as a pound or a couple of dollars per episode. Your support really makes a difference and helps ensure the quality and regularity of the episodes.Following on my previous episodes in the series with Bjørn Hofmann (here and here) where we spoke about the ethics of disease and the moral obligations that flowed from being given a disease label - on this episode we are going to speak more explicitly about clinicians' thinking directed towards ethical problems and the resulting moral judgments they should endeavour to make and the processes which delivers them to those judgments.And so today I'm speaking with Professor Clare Delany. Clare is a Professor in Clinical Education at the University of Melbourne, Department of Medical Education, and a Clinical Ethicist at the Royal Children's Hospital Children's Bioethics Centre and Peter MacCallum Cancer Centre in Melbourne. She also chairs the University of Melbourne Central Human Research Ethics Committee.  Clare's health professional background is in physiotherapy. For the past 15 years, Clare's research and professional work has focused on a combination of clinical education and clinical ethics. Her research interests  include applied health ethics, paediatric bioethics, clinical reasoning, and critical reflection and she has authored more than 100 publications in peer-reviewed journals covering these areas of applied clinical ethics and clinical education.Clare has co-edited the books ‘Learning and Teaching in Clinical Contexts: A Practical Guide' and ‘When Doctors and Parents Disagree: Ethics, Paediatrics and the Zone of Parental Discretion.'So on this episode we speak about: What ethics is in the context of healthcare practice including the ethical principles of autonomy, non-maleficence, beneficence and justice About the interaction and occasional tension between evidence-based practice and ethics-based practice and how ethics can help settle clashes between research evidence, patient values and clinician judgement and experience. What ethical reasoning is and the processes involved In making moral judgements. How it feels to identify an ethical problem which is often intuitive or as Clare describes an ‘ikiness'. Ethical reasoning when the consequences or stakes are high. Communicating risk to patients prior to treatment. Some case examples including patients requesting seemingly ineffective treatments or treatments which the clinician may feel is potentially harmful or not in the patients best interest. How the ethical principles should apply to all healthcare settings, whether public or private but in reality there are differences on how these principles are interpreted and applied in these respective settings. And finally we speak about how ethical reasoning motivates us to be aware of our own assumptions and of the assumptions and values of others which enriches our clinical work and also the therapeutic bond with our patients. So, this was such a wonderful conversation with Clare. She beautifully highlighted the foundational nature yet often prickliness of the ethical dilemmas we all face in practice and shares some extremely useful reasoning strategies to identify, manage and resolve the inevitable ethical moments in our clinical practice.Support the podcast and contribute via Patreon here.If you liked the podcast, you'll love The Words Matter online course and mentoring to develop your clinical expertise  - ideal for all MSK therapists.Follow Words Matter on:Instagram @Wordsmatter_education @TheWordsMatterPodcastTwitter @WordsClinicalFacebook Words Matter - Improving Clinical Communication★ Support this podcast on Patreon ★

By day, she's making molecules dance. By night, this vintage fashionista has a different dance on her mind.

Another GU Cast special from the ProsTIC Preceptorship in Melbourne. Today Dr Renu Eapen welcomes back guest co-host Associate Professor Arun Azad, Medical Oncologist at Peter MacCallum Cancer Centre, to discuss some fantastic translational work going on in his Centre based on our Lutetium PSMA experience. We welcome three great guests to talk about their work. Dr Luc Furic is Head of Translational Prostate Cancer Research at Mac; Dr Louise Kostos is a Medical Oncologist doing a PhD looking at mechanisms of resistance with LuPSMA, and Dr Heidi Fettke is a Post-Docotoral researcher focussing on circulating tumour cells in LuPSMA patients. Plus of course co-host Dr Eapen is also doing a PhD focussing on the immunology of patients receiving LuPSA on the LuTectomy trial. Amazing discussion about the very exciting translational opportunities which LuPSMA presents.Also posted on YouTube if you want to see us in studio Links ProsTIC Preceptorship  ProsTIC Twitter Dr Louise Kostos Twitter

Dr. Steve Ellen.Not only is he a Psychiatrist, Steve is also professor of Psychiatry at Melbourne University and director of the Psychosocial Oncology Program at the Peter MacCallum Cancer Centre in Melbourne, Victoria. Steve has hosted a TV show on SBS called How mad are you? Steve is the co author of “Mental: Everything you never knew you needed to know about Mental Health” & the pocket guide to psychiatry for students.Steve makes frequent TV appearances, he is a weekly radio host on triple R, a radio show called Radiotherapy all in the name of Mental Health. Steve is a very knowledgeable guy with a lot of passion for mental health issues. Throughout his career, Steve has worked with people with all sorts of mental health issues in a variety of professional roles and he himself has suffered with mental health issues. Visit https://www.steveellen.com for more information. Steve's book can be found here: mentalTear It Down is a Six10 Media Production. You can follow us on instagram @six10mediagroup and facebook @six10media. If you want to get in touch you can head to six10mediagroup.com or send an email to info@six10mediagroup.comFind Jamie on Instagram @pultzyIf you need help or are struggling with mental health, you can call lifeline on 13 11 14. Support this show http://supporter.acast.com/tear-it-down. Support this show http://supporter.acast.com/tear-it-down. Hosted on Acast. See acast.com/privacy for more information.